debt_leverage_profile
Minimal long-term debt (~$0 traditional debt); ~$300M cash runway; a 20% rate rise has negligible direct interest expense impact but raises cost of future equity/debt financing.
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct sensitivity; no significant floating-rate debt. Higher rates increase discount rate on future cash flows, compressing valuation multiples for this pre-profit growth company.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Taiwan semiconductor fabrication (TSMC-dependent CMOS ASIC for iQ chip); 2) China-based PCB/assembly manufacturing exposed to US-China trade restrictions.
Inferred
Agent_Inference
international_expansion_readiness
Top international markets (EU, UK, Japan) carry moderate FX risk; EUR/GBP volatility most material. Revenue hedging appears minimal given small international base (~20-25% of revenue).
Inferred
Agent_Inference
geographic_footprint
Primarily US-based (~75-80% revenue); EU and UK secondary markets; JPY and GBP devaluation risks modest but growing as international expansion accelerates.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
TSMC represents a non-substitutable single-source supplier for the proprietary Ultrasound-on-Chip ASIC; switching would require 2-3 year redesign cycle — high lock-in risk.
Inferred
Agent_Inference
business_model_type_primary
Hardware + SaaS hybrid; cloud infrastructure (AWS likely) hosts iQ platform software. A 30-day termination would disrupt cloud connectivity and software delivery significantly.
Inferred
Agent_Inference
business_model_type_secondary
Migration to alternative cloud (GCP/Azure) feasible within 60-90 days but would cause service disruptions; no evidence of multi-cloud redundancy architecture currently deployed.
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling risk; proprietary iQ platform APIs tie device functionality to Butterfly's cloud; hospital EHR integrations (Epic, Cerner) create additional switching friction.
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; Butterfly sells medical imaging hardware and SaaS subscriptions — no investment contract, token, or profit-sharing structure implicated by the Howey Test.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
High GDPR exposure; medical imaging data processed for EU patients requires data residency compliance. CCPA applies to California-based clinical customers. BAA agreements required under HIPAA.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; Butterfly holds <5% of global ultrasound market dominated by GE, Philips, Siemens. No monopolistic behavior or anti-competitive M&A activity flagged.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Approximately 40-50% recurring (iQ+ software subscriptions, enterprise licenses); 50-60% transactional (device hardware sales). Recurring mix growing but hardware still dominates.
Inferred
Agent_Inference
monetization_vector
Dual vector: one-time hardware device sale ($2,000-$3,000 ASP) plus annual software subscription (~$420-$999/year per device); enterprise contracts add recurring base.
Inferred
Agent_Inference
pricing_architecture
Hardware price under pressure from lower-cost competitors (Clarius, Lumify). Subscription tier ($420 basic to $999 pro) has limited pricing power without demonstrated clinical outcome differentiation.
Inferred
Agent_Inference
pricing_power_rating
Low-to-moderate; point-of-care ultrasound commoditizing; Butterfly's software moat (AI-guided imaging) provides some differentiation but insufficient to sustain premium pricing long-term without outcomes data.
Inferred
Agent_Inference
target_gross_margin_bracket
46.9% Gross Margin (Strong (40-60%))
High
SEC-XBRL
churn_vulnerability_index
Moderate free-rider risk; probe purchased outright can be used with basic app features without paid subscription; enterprise renewals more sticky but SMB/individual clinician churn elevated.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth partially sublinear; hardware manufacturing scales with outsourced production, but R&D and clinical sales remain headcount-intensive. Doubling revenue requires ~60-70% headcount growth estimate.
Inferred
Agent_Inference
marginal_cost_of_growth
Hardware COGS ~60-65% of device revenue limits gross margin leverage; software/subscription marginal cost near-zero. Overall blended marginal cost improvement depends on accelerating software mix shift.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Butterfly does not operate a franchise model.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely decreases via enterprise channel leverage, but clinical sales cycle length (6-12 months for hospital systems) remains a structural constraint on scalability.
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; AI imaging algorithm improves with more scan data (data flywheel), but individual users gain no direct benefit from network size — indirect/data-side only.
Inferred
Agent_Inference
asset_efficiency_ratio
-26.0% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; hospital capital budgets compress in recessions, delaying device purchases. However, cost-reduction narrative (replacing expensive cart ultrasound) provides some counter-cyclical value proposition.
Inferred
Agent_Inference
customer_segment_primary
Primary: hospital systems and health networks (enterprise accounts); concentration risk moderate — top 10 enterprise accounts likely represent 25-35% of recurring revenue.
Inferred
Agent_Inference
customer_segment_secondary
Secondary: individual clinicians, medical schools, and military/global health NGOs; fragmented segment with high churn risk and low contract value, reducing concentration risk in this cohort.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
3.4% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001804176
High
SEC-EDGAR
ticker
BFLY
High
SEC-EDGAR